Kartik Sehgal

Dr. Kartik Sehgal

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ANAni Nalbandian
Ani Nalbandian
KSKartik Sehgal
Kartik Sehgal
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
CMClaire McGroder
Claire McGroder
EWElaine Y. Wan
Elaine Y. Wan

10 July 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
KSKartik Sehgal
Kartik Sehgal
NNNandini Nair
Nandini Nair
SMShiwani Mahajan
Shiwani Mahajan
DLDonald W. Landry
Donald W. Landry

30 May 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
BBBehnood Bikdeli
Behnood Bikdeli
MMMahesh V. Madhavan
Mahesh V. Madhavan
AGAakriti Gupta
Aakriti Gupta
DJDavid Jimenez
David Jimenez
JBJohn R. Burton
John R. Burton
Gregory LipGregory Lip
Gregory Lip
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19. * Drs. Bikdeli and Madhavan contributed equally to this manuscript.

1 February 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
KSKartik Sehgal
Kartik Sehgal
RGRitu R. Gill
Ritu R. Gill
PWPage Widick
Page Widick
PBPoorva Bindal
Poorva Bindal
DMDanielle C. McDonald
Danielle C. McDonald
DCDaniel Costa
Daniel Costa
Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 2 or higher compose 34% to 48% of all patients with advanced non–small cell lung cancer (NSCLC).1,2 The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care; 3, capable of limited self-care; 4, completely disabled; and 5, dead. Most landmark clinical trials that led to the approval of pembrolizumab and other immune checkpoint inhibitors (ICIs) by the US Food and Drug Administration (FDA) were conducted in patients with ECOG PS scores of 0 or 1.1,3-5 Due to better perceived tolerance of ICIs compared with cytotoxic chemotherapy, results from these clinical trials have been extrapolated to those with PS scores of 2 or higher, leading to more liberal use of pembrolizumab in this subgroup of patients, who previously might not have been considered eligible for this treatment. This is reflected in the findings from a nationwide patient-level database study that reported an overall increase in the use of systemic therapy at the end of life for patients with NSCLC, driven predominantly by ICIs (along with a concomitant decrease in use of chemotherapy) in the post–ICI approval period.6 Moreover, treatment with ICI within 30 days prior to death was associated with decreased referral to hospice and increased in-hospital deaths.7 While oncologists routinely use PS for decisions regarding chemotherapy,8 rigorous evidence regarding palliative-intent ICI use according to PS is still lacking.

25 June 2015 in Blood
Verified
Journal Article
Open access
PDF file
KSKartik Sehgal
Kartik Sehgal
RDRituparna Das
Rituparna Das
LZLin Zhang
Lin Zhang
RVRakesh Verma
Rakesh Verma
YDYanhong Deng
Yanhong Deng
MDMadhav V. Dhodapkar
Madhav V. Dhodapkar
Key Points: Pomalidomide leads to rapid immune activation in vivo correlating with clinical outcome in relapsed myeloma. Baseline expression of ikaros/aiolos protein in tumor cells is not predictive of outcome.

1 November 2014 in Immunology Letters
Verified
Journal Article
Closed access
KSKartik Sehgal
Kartik Sehgal
KDKavita M. Dhodapkar
Kavita M. Dhodapkar
MDMadhav V. Dhodapkar
Madhav V. Dhodapkar